NCT06762379Recruiting
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 125 (estimated)
- First submitted
- 31 Dec 2024
- Start date
- 20 Dec 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- European Institute of Oncology
- Diseases
- Prostate cancer
- NCT number
- NCT06762379
What you commit to
- Study type: Observational
- Planned participants: 125
- From 20 Dec 2024 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unable to provide written informed consent
Who the study is looking for
- Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| European Institute of Oncology Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.